5-HT receptor partial agonists(Serotonin (5-HT) receptor partial agonists), A1R antagonists(Adenosine A1 receptor antagonists), A2aR antagonists(Adenosine A2a receptor antagonists)

+ [4]

Therapeutic Areas

Nervous System Diseases

Active Indication-

Inactive Indication

Tension-Type Headache

Originator Organization

EMS SA (Brazil)

Active Organization-

Inactive Organization

EMS SA (Brazil)

Drug Highest PhaseDiscontinuedPhase 3

First Approval Date-

Regulation-

Structure

Molecular FormulaC8H10N4O2

InChIKeyRYYVLZVUVIJVGH-UHFFFAOYSA-N

CAS Registry58-08-2

View All Structures (4)

Clinical Trials associated with ERGOTAMINE TARTRATE/Caffeine/ASPIRIN/Homatropine Methylbromide

NCT01408069 / WithdrawnPhase 3

Multicentric, Randomizade, Double Blind, Double Dummy To Non-Inferiority Comparison Of Migrane® Versus Parcel ® For Treatment Of Tensional Cephaleia

The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different associations of drugs in the treatment of patients diagnosed with tensional-type headache in accordance with International Headache Society guidelines.

Start Date-

Sponsor / Collaborator

EMS SA (Brazil)

100 Clinical Results associated with ERGOTAMINE TARTRATE/Caffeine/ASPIRIN/Homatropine Methylbromide

100 Translational Medicine associated with ERGOTAMINE TARTRATE/Caffeine/ASPIRIN/Homatropine Methylbromide

100 Patents (Medical) associated with ERGOTAMINE TARTRATE/Caffeine/ASPIRIN/Homatropine Methylbromide

Literatures (Medical) associated with ERGOTAMINE TARTRATE/Caffeine/ASPIRIN/Homatropine Methylbromide

01 Sep 2015·The Journal of sports medicine and physical fitnessQ4 · MEDICINE

The role of exercise in migraine treatment.

Q4 · MEDICINE

Review

Author: Yetkin, M F ; Ugur, F ; Koseoglu, E ; Bilgen, M

This review aims to provide a comprehensive overview of the literature on the use of exercise for migraine treatment with regard to its efficacy, mechanism of action and role in practice. Many randomized studies have reported the efficacy of prophylactic treatment of migrane with medications such as beta blockers or antiepileptic drugs. Studies on alternative approaches, like aerobic exercise and biofeedback, are however limited but also considered to be effective. Scientific databases were searched with keywords "exercise" and "migraine". The resulting publications were gathered, examined and discussed throughly. Past studies had limitations and were few in number, but more recent randomized controlled studies have concretely provided level of evidence about the effectiveness of exercise in prophylactic treatment of migraine. Core properties of exercise like intensity, duration, frequency, type and warming up period are required to be monitored while treating migraine to increase the beneficial effects and, also to prevent injuries and side effects which may include exertional headache. Isometric neck exercise is helpful when the migraine is accompanied by neck pain. Patient population with low beta endorphin level in blood, high physical fitness and high motivation receives significant benefits from the exercise treatment. The action of exercise on migraine is in general related to neurochemical factors, psychological states and increase in cardivascular and cerebrovascular fitness. Considering its effectiveness and minimal side effects, migraine patients should often be encouraged to practice physical exercise with intensity, frequency and duration that should be carefully instituted to achieve the most beneficial outcome while preventing potential injuries and side effects.

01 Feb 1982·British Journal of Clinical PharmacologyQ2 · MEDICINE

Bioavailability of sublingual ergotamine.

Q2 · MEDICINE

Article

Author: Ibraheem, J. J. ; Paalzow, L. ; Tfelt-Hansen, P.

The bioavailability of sublingual Lingraine (ergotamine tartrate)(I tartrate) [379-79-3] 2 mg in healthy volunteers was compared with the same administration at 0.5 mg to migraine patients.I, above the detection level of 0.1 ng/mL, was not found in the plasma of the volunteers, but it was found above this level in plasma of the migraine patients even after a correction to 0.25 mg.The results indicate that sublingual I at 2 mg cannot have the same bioavailability as 0.25 mg i.m.

100 Deals associated with ERGOTAMINE TARTRATE/Caffeine/ASPIRIN/Homatropine Methylbromide

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Tension-Type Headache	Phase 3	-	EMS SA (Brazil)	03 Aug 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

ERGOTAMINE TARTRATE/Caffeine/ASPIRIN/Homatropine Methylbromide

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation